STALICLA-SA
11.4.2024 13:01:32 CEST | Business Wire | Press release
STALICLA SA, a Swiss clinical-stage biotechnology company focused on advancing precision medicine for brain diseases, announced today the appointment of Thomas Blaettler, to the position of Chief Medical Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240411118139/en/
Thomas Blaettler, MD, joins STALICLA as Chief Medical Officer. (Photo: Business Wire)
Dr. Thomas Blaettler brings a wealth of pharmaceutical development experience and deep insights to help progress STALICLA’s ambitions in CNS conditions. He is a board-certified neurologist with 30 years’ experience in neuroscience, both in clinical residency and within the industry (Novartis, BMS, Roche, Orphazyme, Coave Therapeutics, Vectura Fertin Pharma).
As a clinician, he is driven by the desire to advance clinical research for the benefit of patients who are in dire need of better treatments. He has published both preclinical and clinical research articles in top-tier journals such as Nature, Cell, PNAS and Lancet. With time, he has assumed roles with increasing strategic responsibility, overseeing global clinical development programs from Phase 1 to Phase 3.
Thomas has profound regulatory experience across the globe (EMA, FDA, PMDA, CFDA) from pre-IND interaction to submissions of NDAs and MAAs. As Chief Medical Officer at Orphazyme, he established a clinical development and regulatory organization, overseeing four late-stage development programs. In recent years, he was instrumentally involved in two successful IPOs at the Copenhagen and New York Nasdaq stock exchanges. Thomas completed his Doctor of Medicine at the University of Zurich and gained board certification from the Swiss Society of Neurology in 2003.
“We are delighted to welcome Thomas during a pivotal time where his proven track record in navigating clinical and strategic development will support the advancement of STALICLA’s late-stage Phase 2 and 3 clinical pipelines for precision medicine treatment of neurological and neuropsychiatric disorders. His focus on biomarker lead strategies in CNS drug development is an ideal fit with our science and vision to pioneer precision medicine in the neurodevelopmental disorder space.” - Lynn Durham, CEO & Founder.
“I am thrilled to be joining STALICLA, a biotechnical company that is leading the way in future precision medicine in NDDs and other CNS disorders. Moving away from the one size fits all concept in drug development, with modest if at all treatment effects, to tailored treatments that take into account the clinical and pathophysiological heterogeneity of patient populations will revolutionize the way we treat patients.”- Thomas Blaettler, MD.
About STALICLA
STALICLA SA is a Swiss clinical-stage biopharmaceutical company, pioneering precision treatment in neurodevelopmental and neuropsychiatric disorders. With an advanced clinical pipeline of phase 2 and 3 ready assets and an AI-driven precision neuro medicine platform for patient-drug matching, STALICLA is changing the landscape of brain disease treatment. For more information, please visit: https://stalicla.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240411118139/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vultr Expands European Footprint with 33rd Cloud Data Center Region in Milan, Italy19.5.2026 17:28:00 CEST | Press release
New region strengthens Vultr's commitment to affordable, high-performance cloud infrastructure and Europe's thriving open source and AI ecosystem Vultr, the world’s largest privately-held cloud infrastructure company, today announces the launch of its 33rd global cloud data center region in Milan, coinciding with AI Week 2026 at Fiera Milano Rho, where over 700 international speakers will gather for Europe's largest AI event. Vultr is a platinum sponsor and is also co-hosting the AI Agent Olympics Hackathon with over 1,000 participants. Milan becomes Vultr's ninth European cloud data center region, joining Amsterdam, Frankfurt, London, Madrid, Manchester, Paris, Stockholm, and Warsaw. This launch represents the company's latest expansion of a global network reaching 90% of the world's population within 2–40 milliseconds. Vultr’s cloud data center location will be delivering Vultr’s full-stack AI infrastructure, including Vultr’s flagship cloud compute offering, VX1, in addition to Vult
Global Millennial Capital Closes USD 100 Million IPO Opportunities Fund Focused on AI, Decentralized Financial Infrastructure, and Climate Technologies19.5.2026 17:16:00 CEST | Press release
Global Millennial Capital Ltd. (“GMCL”) today announced the final closing of its inaugural IPO Opportunities Fund at USD 100 million. Raised through a private placement with institutional and professional investors, the fund targets late-stage and special opportunities investments across mid-cap technology companies operating in high-growth sectors, including artificial intelligence, decentralized finance infrastructure, cybersecurity, digital infrastructure, enterprise software, and climate technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519513523/en/ Global Millennial Capital announces the successful final close of its USD 100 million IPO Opportunities Fund, reinforcing its commitment to investing in high-growth technology companies across artificial intelligence, digital infrastructure, cybersecurity, and next-generation financial systems. The fund is designed to capitalize on the increasing number of tech
Miro Takes Aim at the Gap Between AI Potential and Organizational Reality19.5.2026 16:00:00 CEST | Press release
At Canvas 26, Miro establishes its AI platform as the connective layer of the modern AI ecosystem — bringing together teams, agents, and the tools they already work in to turn individual AI productivity into organization-wide transformation Miro®, the AI Innovation Workspace for teams, has announced new innovations across its AI platform, reinforcing its position as the collaboration layer where people, context, and agents from every function converge to solve hard problems, make better decisions, and build the right thing faster. Major upgrades to Miro’s agentic AI tools — including Sidekicks and Flows — alongside new Connectors, help customers close the gap between individual AI productivity and organization-wide transformation. AI is reshaping the pace of work, but often teams are not realising the benefits. In many organizations, a gap has emerged between what individuals can now do and what companies can harness. The reason? Collaboration has fractured. Teams have moved from one m
Wolters Kluwer Medi-Span Selected to Provide Personalized Medication Decision Support at The Christie NHS Foundation Trust19.5.2026 15:30:00 CEST | Press release
Roll-out at largest EU cancer center marks first Medi-Span NHS implementation Wolters Kluwer Health has implemented its industry-leading medication decision support (MDS) solution, Medi-Span®, at the world-renowned specialist oncology center, The Christie NHS Foundation Trust. “The Christie is recognized globally for its excellence and commitment to delivering exceptional patient care,” says Israel Armstrong, Vice President for Medi-Span International at Wolters Kluwer Health. “We’re proud that our first Medi-Span implementation in the NHS should be with such a prestigious institution. We look forward to more collaborations that help streamline processes further and help clinical teams make the most highly informed decisions.” The Christie is a leading expert in cancer care, research and education and is the largest single-site cancer center in Europe. The Christie treats more than 60,000 patients a year and is the first facility in the UK to be accredited as a comprehensive cancer cen
Torq Acquires Jit to Unleash the First Enterprise AI SOC Context Graph—and Rewrite the Future of SecOps19.5.2026 15:00:00 CEST | Press release
With Jit Acquisition, Torq Catapults Enterprise SOCs Into a New Realm of Detailed Contextual Investigations That Drive Precision Decision-Making Torq, the established agentic security operations leader, today announced the acquisition of Jit, the Boston-based AI Context Graph cybersecurity pioneer. This move marks a dramatic leap forward for the Torq AI SOC Platform by ensuring agentic investigations are precisely informed via organization-specific contextual data. This shift redefines agentic reasoning, moving beyond static facts such as users, devices and their relationships, to prioritize live, dynamic contextual data overlaid on top, including business drivers, and the real-time state of the enterprise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519044833/en/ Instead of acting on fragmented data or having investigations triggered by a single alert, Torq AI operates with a unified, continuously-updated, contextual
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom